Arc­turus re­verse merges in­to the mar­ket, steer­ing RNA projects to the clin­ic

Is­rael’s Al­co­bra start­ed out 2017 with a dis­as­ter, forced to con­cede that their Phase III study of MDX — its on­ly drug in the clin­ic — had flopped against a place­bo. The news ru­ined its share price $AD­HD and set in mo­tion the search for a new fu­ture that end­ed with the news that it struck a re­verse merg­er deal with the RNA biotech Arc­turus.

Arc­turus will now steer its way in­to the pub­lic mar­ket with a com­bined com­pa­ny that has $40 mil­lion in cash and some new op­tions on rais­ing more. The biotech al­so has a few part­ners, in­clud­ing Take­da (on NASH) and Ul­tragenyx, with plans to move in­to the clin­ic for the first time.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.